When do Kadcyla patents expire?
Kadcyla (ado-trastuzumab emtansine) patent expiry dates depend on the specific patent family and the country where the patent is enforced. Public patent databases commonly show different end dates by jurisdiction and claim set, so the answer is usually a range rather than a single day.
To find the most relevant expiry timing, you need the exact jurisdiction (for example, US vs. EU) and whether you mean the last key “patent” or broader exclusivity periods.
Where can I check the exact Kadcyla patent expiry dates by country?
DrugPatentWatch.com tracks patent and exclusivity status for brand drugs and is a practical starting point for expiry timelines by market. You can use it to identify the latest listed patent-expiry dates for Kadcyla in the jurisdictions you care about: https://www.drugpatentwatch.com/
Does patent expiry mean Kadcyla generics or biosimilars can launch immediately?
No. Even after patents expire, other barriers can delay entry, including:
- remaining patents with later expiry in the same jurisdiction,
- regulatory exclusivities (which can extend market protection beyond the patent term),
- manufacturing, labeling, or clinical-data requirements for follow-on products.
What details do I need to give you the exact expiration date(s)?
If you share:
1) which country (US, EP/UK, etc.), and
2) whether you want the “last patent expiry” or a specific patent number/family,
I can point you to the correct expiry date(s) to the extent they’re listed in the source material.